MedPath

The predictive value of 18F-FDG-PET to demonstrate disease activity in patients with relapsed multiple myeloma; a pilot study

Completed
Conditions
Kahler's disease
10018865
Registration Number
NL-OMON32803
Lead Sponsor
niversitair Medisch Centrum Groningen
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
15
Inclusion Criteria

Relapsed multiple myeloma patients that demonstrate increased disease activity

Exclusion Criteria

-Ineligible to perform a scan
-Age <18 years.
-Pregnancy.
-Severe kidney dysfunction; serum-creatinine >=250 µM.

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>- To define the increase of FDG-PET uptake in relapsed MM in comparison to SRS<br /><br>and X-ray examination.<br /><br></p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Not applicable</p><br>
© Copyright 2025. All Rights Reserved by MedPath